RxDoctor Payments Data

Michelle Hogue, NP

Family · Greenwood Village, CONPI 1396424743

Payments from drug & device makers

$5,478in general payments, 2019–2025

Across 81 payments — averaging $67.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Saluda Medical Americas, Inc.$3K
  • Boston Scientific$2K
  • Vertos Medical, Inc.$143
  • SPR Therapeutics, Inc$107
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$87
  • Collegium Pharmaceutical, Inc.$62
  • plus $251 from 8 others

What the payments were for

  • Travel & lodging$1,76332%
  • Food & beverage$3,71668%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,478 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$66,654
Medicare patients
318
Services billed
950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate42$27,310
Buprenorphine83$23,355
OxycontinOxycodone Hcl20$16,373
BelbucaBuprenorphine Hcl15$10,853
Fentanyl11$5,996
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen197$4,250
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen130$4,069
Oxycodone Hcl213$4,024
Pregabalin126$3,910
Morphine Sulfate ErMorphine Sulfate73$2,366
Gabapentin156$2,336
Lidocaine12$1,994
Celecoxib72$1,467
Tramadol Hcl ErTramadol Hcl21$1,407
Duloxetine Hcl94$1,264

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca$62$38,16357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Greenwood Village

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →